On July 15, CSPC Pharmaceutical rose 3.08% in regular trading, trading at HKD 8.3/share, with turnover of HKD 114 million.

On the news front, the company announced on July 14 that its self-developed albumin-bound docetaxel injection combined with annituzumab has been granted Breakthrough Therapy Designation by China's National Medical Products Administration. The proposed indication is first-line treatment of unresectable or metastatic HER2-positive adult breast cancer, providing an accelerated regulatory pathway for the combination therapy.

Additionally, Huatai-PineBridge Fund increased its holdings by 7.368 million shares on July 10 at approximately HKD 8.14 per share, totaling about HKD 59.96 million. The company also received a USD 25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for developing novel long-acting peptide drugs, signaling steady research progress. Multiple positive catalysts converged to boost market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)